Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991

医学 前列腺癌 危险系数 临床终点 泌尿科 雄激素抑制 内科学 放射治疗 癌症 前列腺 肿瘤科 随机对照试验 外科 置信区间
作者
M. Bolla,P. Maingon,C. Carrié,S. Villà,Petros Kitsios,Philip Poortmans,Santhanam Sundar,Elzbieta M. van der Steen‐Banasik,John Armstrong,Jean-François Bosset,Fernanda Herrera,Bradley R. Pieters,Annerie Slot,Amit Bahl,Rahamim Ben-Yosef,Dirk Boehmer,Christopher Scrase,Laurette Renard,Emad Shash,Corneel Coens
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:34 (15): 1748-1756 被引量:207
标识
DOI:10.1200/jco.2015.64.8055
摘要

Purpose Up to 30% of patients who undergo radiation for intermediate- or high-risk localized prostate cancer relapse biochemically within 5 years. We assessed if biochemical disease-free survival (DFS) is improved by adding 6 months of androgen suppression (AS; two injections of every-3-months depot of luteinizing hormone–releasing hormone agonist) to primary radiotherapy (RT) for intermediate- or high-risk localized prostate cancer. Patients and Methods A total of 819 patients staged: (1) cT1b-c, with prostate-specific antigen (PSA) ≥ 10 ng/mL or Gleason ≥ 7, or (2) cT2a (International Union Against Cancer TNM 1997), with no involvement of pelvic lymph nodes and no clinical evidence of metastatic spread, with PSA ≤ 50 ng/mL, were centrally randomized 1:1 to either RT or RT plus AS started on day 1 of RT. Centers opted for one dose (70, 74, or 78 Gy). Biochemical DFS, the primary end point, was defined from entry until PSA relapse (Phoenix criteria) and clinical relapse by imaging or death of any cause. The trial had 80% power to detect hazard ratio (HR), 0.714 by intent-to-treat analysis stratified by dose of RT at the two-sided α = 5%. Results The median patient age was 70 years. Among patients, 74.8% were intermediate risk and 24.8% were high risk. In the RT arm, 407 of 409 patients received RT; in the RT plus AS arm, 403 patients received RT plus AS and three patients received RT only. At 7.2 years median follow-up, RT plus AS significantly improved biochemical DFS (HR, 0.52; 95% CI, 0.41 to 0.66; P < .001, with 319 events), as well as clinical progression-free survival (205 events, HR, 0.63; 95% CI, 0.48 to 0.84; P = .001). In exploratory analysis, no statistically significant interaction between treatment effect and dose of RT could be evidenced (heterogeneity P = .79 and P = .66, for biochemical DFS and progression-free survival, respectively). Overall survival data are not mature yet. Conclusion Six months of concomitant and adjuvant AS improves biochemical and clinical DFS of intermediate- and high-risk cT1b-c to cT2a (with no involvement of pelvic lymph nodes and no clinical evidence of metastatic spread) prostatic carcinoma, treated by radiation.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
传奇3的应助被斯南采纳,获得30
1秒前
kui完成签到,获得积分20
2秒前
2秒前
暮冬十二完成签到 ,获得积分10
3秒前
279完成签到,获得积分10
3秒前
3秒前
赘婿的应助被超级盼烟采纳,获得10
4秒前
共享精神的应助被舒适沛蓝采纳,获得10
5秒前
6秒前
wg发布了新的文献求助10
6秒前
7秒前
molihuakai的应助被科研通管家采纳,获得10
7秒前
所所的应助被科研通管家采纳,获得10
7秒前
汉堡包的应助被科研通管家采纳,获得10
8秒前
小二郎的应助被科研通管家采纳,获得10
8秒前
爆米花的应助被kui采纳,获得10
8秒前
8秒前
syvshc的应助被科研通管家采纳,获得10
8秒前
田様的应助被科研通管家采纳,获得10
8秒前
Nole的应助被tib采纳,获得10
8秒前
小二郎的应助被科研通管家采纳,获得10
8秒前
8秒前
8秒前
天天快乐的应助被科研通管家采纳,获得10
8秒前
9秒前
9秒前
大模型的应助被科研通管家采纳,获得10
9秒前
9秒前
syvshc的应助被科研通管家采纳,获得10
9秒前
英姑的应助被幸运周周周采纳,获得10
9秒前
早上好完成签到,获得积分10
10秒前
10秒前
Lixin发布了新的文献求助10
11秒前
11秒前
阳佟水蓉发布了新的文献求助10
12秒前
浩想椰汁完成签到,获得积分20
12秒前
Voskov完成签到,获得积分10
13秒前
TCMning发布了新的文献求助10
13秒前
14秒前
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188394
求助须知:如何正确求助?哪些是违规求助? 9576268
关于积分的说明 21846207
捐赠科研通 7786486
什么是DOI,文献DOI怎么找? 3435317
关于科研通互助平台的介绍 2559618
邀请新用户注册赠送积分活动 2482322